Immunovant(IMVT) - 2026 Q1 - Quarterly Results

Financial Performance - As of June 30, 2025, Immunovant's cash and cash equivalents totaled approximately $598.9 million, providing runway for announced indications through GD readout expected in 2027[6] - Research and development (R&D) expenses for the three months ended June 30, 2025, were $101.2 million, an increase of 34% from $75.5 million for the same period in 2024[7] - General and administrative (G&A) expenses for the three months ended June 30, 2025, were $26.0 million, up from $18.8 million in the prior year, reflecting a 38% increase[10] - The net loss for the three months ended June 30, 2025, was $120.6 million ($0.71 per common share), compared to a net loss of $87.2 million ($0.60 per common share) for the same period in 2024, representing a 38% increase in net loss[11] - Non-GAAP net loss for the three months ended June 30, 2025, was $102.1 million, compared to $73.8 million for the same period in 2024, indicating a 38% increase[11] - The total operating expenses for the three months ended June 30, 2025, were $127.2 million, compared to $94.3 million for the same period in 2024, reflecting a 35% increase[18] Clinical Development - Immunovant initiated a second potentially registrational trial for IMVT-1402 in Graves' disease (GD) and Sjögren's disease (SjD) in June 2025, with all clinical development timelines remaining on track[3] - Results from the open-label portion of the potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) are expected in calendar year 2026[5] - Top-line results from the proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) are also anticipated in calendar year 2026[5] Share Information - As of June 30, 2025, there were 171,069,176 shares of common stock issued and outstanding[12]